These results clearly support the notion that the previously uncharacterized EGFR/EZH2/NFAT5 axis identified may explain the high probability of tumorigenesis and why only a small fraction of GBM patients respond to TMZ. This evidence concerns the gene NFAT5 and glioblastoma.